Advertisement

Osteoporosis Diagnosis

  • Claudio Marcocci
  • Federica Saponaro
Chapter

Abstract

Osteoporosis is a systemic disease characterized by decreased bone strength and an increased risk of fracture. Bone strength progressively declines with aging, and therefore osteoporosis is considered an inevitable process and is not approached as a relevant clinical problem. However, several intervening factors may accelerate this involutional process. One of the major reasons is that osteoporosis is asymptomatic until a fracture occurs, and therefore both the physician and the patients fail to appreciate its importance. As a matter of fact, many patients with osteoporosis and/or at increased risk of fracture are still underdiagnosed and undertreated.

References

  1. 1.
    Bonjour JP, Chevalley T. Pubertal timing, bone acquisition, and risk of fracture throughout life. Endocr Rev. 2014;35(5):820–47.  https://doi.org/10.1210/er.2014-1007.CrossRefPubMedGoogle Scholar
  2. 2.
    Gaddini GW, Turner RT, Grant KA, Iwaniec UT. Alcohol: a simple nutrient with complex actions on bone in the adult skeleton. Alcohol Clin Exp Res. 2016;40(4):657–71.  https://doi.org/10.1111/acer.13000.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA, Pols H, Tenenhouse A. Alcohol intake as a risk factor for fracture. Osteoporos Int. 2005;16(7):737–42.  https://doi.org/10.1007/s00198-004-1734-y.CrossRefPubMedGoogle Scholar
  4. 4.
    Bijelic R, Milicevic S, Balaban J. Risk factors for osteoporosis in postmenopausal women. Med Arch. 2017;71(1):25–8.  https://doi.org/10.5455/medarh.2017.71.25-28.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Brook JS, Balka EB, Zhang C. The smoking patterns of women in their forties: their relationship to later osteoporosis. Psychol Rep. 2012;110(2):351–62.  https://doi.org/10.2466/13.18.PR0.110.2.351-362.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Pietschmann F, Breslau NA, Pak CY. Reduced vertebral bone density in hypercalciuric nephrolithiasis. J Bone Miner Res. 1992;7(12):1383–8.  https://doi.org/10.1002/jbmr.5650071205.CrossRefPubMedGoogle Scholar
  7. 7.
    Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception. 2008;77(2):67–76.  https://doi.org/10.1016/j.contraception.2007.10.005.CrossRefPubMedGoogle Scholar
  8. 8.
    Thornton D, Gordon CM. Restrictive eating disorders and skeletal health in adolescent girls and young women. Calcif Tissue Int. 2017;100(5):449–60.  https://doi.org/10.1007/s00223-016-0164-0.CrossRefPubMedGoogle Scholar
  9. 9.
    Siris ES, Adler R, Bilezikian J, Bolognese M, Dawson-Hughes B, Favus MJ, Harris ST, Jan de Beur SM, Khosla S, Lane NE, Lindsay R, Nana AD, Orwoll ES, Saag K, Silverman S, Watts NB. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int. 2014;25(5):1439–43.  https://doi.org/10.1007/s00198-014-2655-z.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Melton LJ, Atkinson EJ, Cooper C, O'Fallon WM, Riggs BL. Vertebral fractures predict subsequent fractures. Osteoporos Int. 1999;10(3):214–21.CrossRefPubMedGoogle Scholar
  11. 11.
    Mackey DC, Lui LY, Cawthon PM, Bauer DC, Nevitt MC, Cauley JA, Hillier TA, Lewis CE, Barrett-Connor E, Cummings SR, Study of Osteoporotic F, Osteoporotic Fractures in Men Study Research G. High-trauma fractures and low bone mineral density in older women and men. JAMA. 2007;298(20):2381–8.  https://doi.org/10.1001/jama.298.20.2381.CrossRefPubMedGoogle Scholar
  12. 12.
    Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson LM, Lamb SE. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2012;9:CD007146.  https://doi.org/10.1002/14651858.CD007146.pub3.CrossRefGoogle Scholar
  13. 13.
    Smulders E, Weerdesteyn V, Groen BE, Duysens J, Eijsbouts A, Laan R, van Lankveld W. Efficacy of a short multidisciplinary falls prevention program for elderly persons with osteoporosis and a fall history: a randomized controlled trial. Arch Phys Med Rehabil. 2010;91(11):1705–11.  https://doi.org/10.1016/j.apmr.2010.08.004.CrossRefPubMedGoogle Scholar
  14. 14.
    Compston J. Clinical question: what is the best approach to managing glucocorticoid-induced osteoporosis? Clin Endocrinol. 2011;74(5):547–50.  https://doi.org/10.1111/j.1365-2265.2011.03994.x.CrossRefGoogle Scholar
  15. 15.
    Paggiosi MA, Peel NF, Eastell R. The impact of glucocorticoid therapy on trabecular bone score in older women. Osteoporos Int. 2015;26(6):1773–80.  https://doi.org/10.1007/s00198-015-3078-1.CrossRefPubMedGoogle Scholar
  16. 16.
    Panday K, Gona A, Humphrey MB. Medication-induced osteoporosis: screening and treatment strategies. Ther Adv Musculoskelet Dis. 2014;6(5):185–202.  https://doi.org/10.1177/1759720X14546350.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Tufano A, Coppola A, Contaldi P, Franchini M, Minno GD. Oral anticoagulant drugs and the risk of osteoporosis: new anticoagulants better than old? Semin Thromb Hemost. 2015;41(4):382–8.  https://doi.org/10.1055/s-0034-1543999.CrossRefPubMedGoogle Scholar
  18. 18.
    Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int. 2007;18(4):427–44.  https://doi.org/10.1007/s00198-006-0253-4.CrossRefPubMedGoogle Scholar
  19. 19.
    Yamagishi S, Maeda S, Matsui T, Ueda S, Fukami K, Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochim Biophys Acta. 2012;1820(5):663–71.  https://doi.org/10.1016/j.bbagen.2011.03.014.CrossRefPubMedGoogle Scholar
  20. 20.
    Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj Fuleihan G, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV, Task Force of the FI. Interpretation and use of FRAX in clinical practice. Osteoporos Int. 2011;22(9):2395–411.  https://doi.org/10.1007/s00198-011-1713-z.CrossRefPubMedGoogle Scholar
  21. 21.
    Compston J. Osteoporosis: advances in risk assessment and management. Clin Med. 2016;16(Suppl 6):s121–4.  https://doi.org/10.7861/clinmedicine.16-6-s121.CrossRefGoogle Scholar
  22. 22.
    Adami S, Bianchi G, Brandi ML, Di Munno O, Frediani B, Gatti D, Giannini S, Girasole G, Minisola G, Minisola S, Nuti R, Pedrazzoni M, Rossini M, Varenna M. Validation and further development of the WHO 10-year fracture risk assessment tool in Italian postmenopausal women: project rationale and description. Clin Exp Rheumatol. 2010;28(4):561–70.PubMedGoogle Scholar
  23. 23.
    Naylor K, Eastell R. Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol. 2012;8(7):379–89.  https://doi.org/10.1038/nrrheum.2012.86.CrossRefPubMedGoogle Scholar
  24. 24.
    Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994;79(6):1693–700.  https://doi.org/10.1210/jcem.79.6.7989477.CrossRefPubMedGoogle Scholar
  25. 25.
    Diez-Perez A, Naylor KE, Abrahamsen B, Agnusdei D, Brandi ML, Cooper C, Dennison E, Eriksen EF, Gold DT, Guanabens N, Hadji P, Hiligsmann M, Horne R, Josse R, Kanis JA, Obermayer-Pietsch B, Prieto-Alhambra D, Reginster JY, Rizzoli R, Silverman S, Zillikens MC, Eastell R, Adherence Working Group of the International Osteoporosis F, the European Calcified Tissue S. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int. 2017;28(3):767–74.  https://doi.org/10.1007/s00198-017-3906-6.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Lewiecki EM, Laster AJ. Clinical review: clinical applications of vertebral fracture assessment by dual-energy X-ray absorptiometry. J Clin Endocrinol Metab. 2006;91(11):4215–22.  https://doi.org/10.1210/jc.2006-1178.CrossRefPubMedGoogle Scholar
  27. 27.
    Jiang G, Eastell R, Barrington NA, Ferrar L. Comparison of methods for the visual identification of prevalent vertebral fracture in osteoporosis. Osteoporos Int. 2004;15(11):887–96.  https://doi.org/10.1007/s00198-004-1626-1.CrossRefPubMedGoogle Scholar
  28. 28.
    Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8(9):1137–48.  https://doi.org/10.1002/jbmr.5650080915.CrossRefPubMedGoogle Scholar
  29. 29.
    Eastell R, Cedel SL, Wahner HW, Riggs BL, Melton LJ. Classification of vertebral fractures. J Bone Miner Res. 1991;6(3):207–15.  https://doi.org/10.1002/jbmr.5650060302.CrossRefPubMedGoogle Scholar
  30. 30.
    McCloskey EV, Spector TD, Eyres KS, Fern ED, O'Rourke N, Vasikaran S, Kanis JA. The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int. 1993;3(3):138–47.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Clinical and Experimental MedicineUniversity of Pisa, Endocrine Unit 2, University Hospital of PisaPisaItaly

Personalised recommendations